Marc Chamberlain, M.D., has been appointed as the Chief Medical Officer at Starlight Therapeutics.
Starlight Therapeutics is a Dallas-based Lantern Pharma subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options.
In his role as CMO, Chamberlain will oversee the company’s upcoming clinical trials focused on several serious and complex brain-related conditions: glioblastoma and other high-grade gliomas (aggressive types of brain tumor), brain metastases in adults (secondary brain tumors originating from cancer elsewhere in the body), and two types of pediatric brain tumors — atypical teratoid rhabdoid tumors (ATRT) and diffuse intrinsic pontine glioma (DIPG)....
